Review ArticlePathophysiology, Clinical Manifestations, and Treatment of Lichen Sclerosus: A Systematic Review
Section snippets
EPIDEMIOLOGY
The exact prevalence of LS is unknown and generally considered underreported because of provider lack of familiarity and asymptomatic presentations or discomfiture.13 Early estimations based on referrals to dermatology practices suggest the prevalence is between 1:300 and 1:1000.14 The disease affects both women and men, though the ratio of women to men based on current estimates is approximately 3:1 to 10:1.15 A report from a general gynecology practice estimated the prevalence to be 1.7%
METHODS
The following search query was entered into Medline/PubMed and Embase: [“physiopathology” OR “etiology” OR “pathophysiology” OR “pathogenesis” OR “etiology” OR “physiopathology” OR “aetiology” OR “gene”] AND [“lichen sclerosus et atrophicus” OR “vulvar lichen sclerosus” OR “balanitis xerotica obliterans”]. This query yielded 1143 articles. We excluded non-English articles and nonhuman studies. We included only original research and articles published in 1970 or later. Two independent reviewers
LS in Men
Meatal stenosis and urethral stricture are also seen in men with LS and can result in significant morbidity for those affected with recurrence rates between 20% and 50%.38,39 If untreated, an inflexible phimotic foreskin may constrict the glans, which can manifest as a scrotalized appearance of penile shaft skin. Involvement of the meatus (Supplemental Fig. 2) and urethra in men can lead to urinary morbidity including changes in urinary stream and dysuria, or in severe cases urinary retention
Clinical Risk Factors
LS may be associated with environmental factors and nonautoimmune comorbidities. The most commonly cited risk in men is lack of circumcision.52,53 Mallon et al noted an age-adjusted odds ratio of 53.55 (95% confidence interval [CI]: 7.24-395.88) in association to uncircumcised male patients.53 Injury to genital skin can increase the risk of LS as can friction, genital piercings for jewelry, and surgery.54,55 An investigation into LS and medical comorbidities demonstrated an association between
CONCLUSION
Although the etiology of LS remains unknown, infectious, anti-immune, or chronic irritation may all play a role in its presentation. Future research should explore the intersection of infections, skin microtrauma, and immune dysregulation leading to this disease state. Clinically, LS has the potential to progress to malignancy or cause debilitating changes to normal tissues. Topical corticosteroids are the current mainstay of medical treatment. Surgical therapy should avoid use of genital skin
References (127)
- et al.
Lichen sclerosus: review of the literature and current recommendations for management
J Urol
(2007) - et al.
Metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 are increased in vulvar lichen sclerosus
Eur J Obstet Gynecol Reprod Biol
(2012) - et al.
Autoantibodies to extracellular matrix protein 1 in lichen sclerosus
Lancet (London, England)
(2003) - et al.
Lichen sclerosus: epidemiological distribution in an equal access health care system
J Urol
(2011) - et al.
A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus
J Am Acad Dermatol
(2011) - et al.
Fossa navicularis reconstruction: impact of stricture length on outcomes and assessment of extended meatotomy (first stage Johanson) maneuver
J Urol
(2007) - et al.
Buccal mucosal urethroplasty for balanitis xerotica obliterans related urethral strictures: the outcome of 1 and 2-stage techniques
J Urol
(2005) - et al.
Lichen sclerosus of the male genitalia and urethra: surgical options and results in a multicenter international experience with 215 patients
Eur Urol
(2009) Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid
Obstet Gynecol
(1999)- et al.
Penile cancer among patients with genital lichen sclerosus
J Am Acad Dermatol
(1999)
Penile carcinoma in patients with genital lichen sclerosus: a multicenter survey
J Urol
Vulvar lichen sclerosus and squamous cell carcinoma: a cohort, case control, and investigational study with historical perspective; implications for chronic inflammation and sclerosis in the development of neoplasia
Hum Pathol
Lichen sclerosus comorbidities and complications from a national sample of patients treated with urethroplasty
Urol Pract
Genetic aspects of vulvar lichen sclerosus
Am J Obstet Gynecol
Lichen sclerosus
Lancet (London, England)
Three-dimensional imaging reveals major changes in skin microvasculature in lipoid proteinosis and lichen sclerosus
J Dermatol Sci
Fitzpatrick's Dermatology in General Medicine [Electronic Resource]
British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018
Br J Dermatol
An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of microRNA-155
J Invest Dermatol
Differential expression of connective tissue growth factor and extracellular matrix proteins in lichen sclerosus
J Eur Acad Dermatol Venereol
T cells reactive with the NC16A domain of BP180 are present in vulval lichen sclerosus and lichen planus
J Eur Acad Dermatol Venereol
IP10/CXCL10 - CXCR3 interaction: a potential self-recruiting mechanism for cytotoxic lymphocytes in lichen sclerosus et atrophicus
Acta Derm Venereol
Cytokine alterations in lichen sclerosus: an immunohistochemical study
Br J Dermatol
Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus
Hum Genet
Expression of transglutaminase in foreskin of children with balanitis xerotica obliterans
Int J Mol Sci
British Association of Dermatologists [Collective Name]. British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010
Br J Dermatol
Lichen sclerosus
Clin Exp Dermatol
Evidence-based (S3) guideline on (anogenital) lichen sclerosus
J Eur Acad Dermatol Venereol
Prevalence of vulvar lichen sclerosus in a general gynecology practice
J Reprod Med
A study of clinical and aetiological factors and possible associations of lichen sclerosus in males
Australas J Dermatol
Lichen sclerosus et atrophicus
Trans St Johns Hosp Dermatol Soc
Balanitis xerotica obliterans: epidemiologic distribution in an equal access health care system
South Med J
Clinical parameters in male genital lichen sclerosus: a case series of 329 patients
J Eur Acad Dermatol Venereol
Vulvar lichen sclerosus
J Low Genit Tract Dis
First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability
Br J Dermatol
Treatment of male genital lichen sclerosus with clobetasol propionate and maintenance with either methylprednisolone aceponate or tacrolimus: a retrospective study
J Dermatol Treat
Obesity-related male genital lichen sclerosus
J Eur Acad Dermatol Venereol
Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement
J Dermatol
Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus
J Am Acad Dermatol
The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force
J Am Acad Dermatol
The treatment of balanitis xerotica obliterans
BJU Int
The contemporary management of urethral strictures in men resulting from lichen sclerosus
Transl Androl Urol
UVA1 phototherapy for genital lichen sclerosus
Clin Exp Dermatol
Treatment of lichen sclerosus with carbon dioxide laser vaporization
Br J Dermatol
Understanding the relationship between chronic systemic disease and lichen sclerosus urethral strictures
J Urol
Urethroplasty for balanitis xerotica obliterans
Br J Urol
Lichen sclerosus and isolated bulbar urethral stricture disease
J Urol
Incidence of urethral stricture in patients with adult acquired buried penis
Adv Urol
Vulvar lichen sclerosus in women is associated with lower urinary tract symptoms
Int Urogynecol J
Relation of lichen sclerosus et atrophicus of the vulva to development of carcinoma
Obstet Gynecol
Cited by (0)
Declaration of Interest: None.